Who is Artrya?
Artrya is an innovative medical technology company ushering in new standards for coronary artery disease detection, diagnosis and care
Coronary artery disease is the leading cause of death in developed countries1 – but diagnostic methods for this disease have remained unchanged for nearly 50 years.
Harnessing the power of machine learning, we’re paving the way for swift, accurate and non-invasive diagnosis of coronary artery disease to drive precision medicine and save lives.
Artrya is an AI-driven MedTech company, founded in 2019, and brought to life in Perth, Australia. Artrya was co-founded by John Konstantopoulos and John Barrington AM, who came together with a mutual passion for disruptive technologies and improving health outcomes across the globe. Artrya sees heart disease in a new way, using data-driven solutions to assist physicians with cardiovascular diagnosis.
Our innovative diagnostic support solution, Artrya Salix, accurately assesses and detects plaque features, in real-time, without the need for invasive interventions.
The right treatment. For the right patient. At the right time.
Traditional diagnostic processes for coronary artery disease have avoided sophisticated analysis because it was time-consuming and required significant manual inputs. At Artrya, we’re paving the way for a diagnostic process that is better for patients, more effective for healthcare professionals and more efficient for healthcare systems.
The heart behind our name
Meaning of Artrya
Ar-tree-a (phonetic) Artrya is a play on the word ‘artery,’ the vessel which takes oxygen-rich blood from the heart to other parts of the body.
The word artery is based on the Greek word aρτηρiα (arteria), meaning air and to keep.
This meaning underpins our mission to use advanced, AI-based technology to reduce the number of heart attacks that occur around the world each year and, fundamentally, save lives.
Represented by the world’s leading cardiologists
Dr Jacque Sokolov
Chairman of Board and Chair of Clinical Advisory Board, Artrya USA Inc.
Professor Girish Dwivedi, MD
Chief Scientific Officer
Wesfarmers Chair in Cardiology at the University of Western Australia (Harry Perkins Institute of Medical Research) and Consultant Cardiologist at Fiona Stanley Hospital.
Dr Jack Lewin
Clinical Advisory Board Member, Artrya USA Inc.
Principal of American Health NY, former CEO of American College of Cardiologists.
Professor Benjamin Chow, MD
Clinical Advisory Board Member, Artrya USA Inc.
Clinical Cardiologist and Clinician Investigator at the University of Ottawa Heart Institute.
References:
- Brown JC, Gerhardt TE, Kwon E. Risk Factors For Coronary Artery Disease. 2021 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32119297.
- Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O'Connor RE, Ross MA, Shaw LJ. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):e368–e454. Study link. Published May 11, 2022.
Precise diagnosis. Personalized treatment. Preventative care.
Choose Artrya as your trusted clinical partner.
Contact us todayCoronary artery disease.We see you.